AbbVie’s hepatitis C regimen won FDA approval Friday, becoming the second entrant in what is already a huge market for interferon-free HCV treatments. The Viekira Pak will cost $83,319 for 12 weeks, in line with forecasts and undercutting Gilead Sciences’ (GILD) $94,500 for the same treatment length. The AbbVie (ABBV) regimen consists of three drugs: ombitasvir, paritaprevir (first developed by Enanta Pharmaceuticals (ENTA) and
Juno Therapeutics soared 46% in Friday’s trading debut, the latest sign of investor demand for a new class of cancer-curing firms and for biotechs overall. Juno (JUNO) raised $265 million late Thursday in its IPO with an initial market capitalization of $2.2 billion, the highest valuation for a biotech IPO in 2014, according to IPO (IPO) ETF manager Renaissance Capital. Juno sold 11 million shares at 24. It initially planned to
Two big winners out of four will have to suffice for investors as a group of enterprise software companies — all of which play in the Big Data and/or cloud markets — made their stock market debuts Friday. New Relic (NEWR) and Hortonworks (HDP) got the most attention. New Relic stock jumped 48% to 33.99, as the company raised $115 million on a down day for the market. Hortonworks stock climbed 65% to 26.38. The company raised $100